Skip to Main content Skip to Navigation
Journal articles

EHD2 is a Predictive Biomarker of Chemotherapy Efficacy in Triple Negative Breast Carcinoma

Abstract : EHD2 is a mechanotransducing ATPase localized in caveolae invaginations at the plasma membrane. EHD2 has recently been associated with several human cancers, however the significance of EHD2 transcript levels in cancer prognosis remains debated. Breast cancer is the most commonly occurring cancer in women and prognosis is variable depending on the subtypes. Triple negative breast cancer (TNBC) often has a poor therapeutic response. The aim of this study was to assess the prognostic significance of EHD2 transcripts and protein expression levels in breast carcinomas. We found that low EHD2 levels were associated with enhanced proliferation, migration and invasion of TNBC cells. EHD2 expression was significantly reduced in TNBC tissues and the loss of EHD2 led to higher expression of the pro-tumoral cytokine IL-8. In apparent contradiction with in vitro data, multivariate analysis of two independent cohorts of breast cancer patients revealed that low EHD2 was in fact associated with good prognosis in the highly proliferative TNBC subtype. Accordingly, TNBC low EHD2 expressers were found to benefit the most from chemotherapy when compared to all subtypes of breast cancers. Our study validates EHD2 expression level as an independent prognostic factor of metastasis-free survival and as a new predictive marker of chemotherapy efficacy in TNBC patients.
Complete list of metadatas

Cited literature [38 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-02864579
Contributor : Myriam Bodescot <>
Submitted on : Thursday, June 11, 2020 - 10:50:59 AM
Last modification on : Monday, October 19, 2020 - 11:00:20 AM

File

s41598-020-65054-5.pdf
Publication funded by an institution

Identifiers

Collections

Citation

Wei-Wei Shen, Ivan Bièche, Laetitia Fuhrmann, Sophie Vacher, Anne Vincent-Salomon, et al.. EHD2 is a Predictive Biomarker of Chemotherapy Efficacy in Triple Negative Breast Carcinoma. Scientific Reports, Nature Publishing Group, 2020, 10 (1), pp.7998. ⟨10.1038/s41598-020-65054-5⟩. ⟨inserm-02864579⟩

Share

Metrics

Record views

33

Files downloads

58